Patents by Inventor Ronald P. Taylor

Ronald P. Taylor has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibody targeting cell surface deposited complement protein C3d and use thereof
    Patent number: 11384139
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Grant
    Filed: July 27, 2018
    Date of Patent: July 12, 2022
    Assignees: The United States of Americans represented by the Secretary, Department of Health and Human Services, University of Virginia Patent Foundation
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
    Publication number: 20190055305
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Application
    Filed: July 27, 2018
    Publication date: February 21, 2019
    Applicants: The United States of America,as represented by the Secretary,Department of Health and Human Services, University of Virginia Patent Foundation,d/b/a University of Virginia Licensing & Ventures Group
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • Antibody targeting cell surface deposited complement protein C3d and use thereof
    Patent number: 10035848
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Grant
    Filed: January 8, 2015
    Date of Patent: July 31, 2018
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, University of Virginia Patent Foundation
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • ANTIBODY TARGETING CELL SURFACE DEPOSITED COMPLEMENT PROTEIN C3d AND USE THEREOF
    Publication number: 20160333082
    Abstract: An anti-C3d antibody or antibody fragment; method for use thereof to kill cancer cells; and related methods and compositions.
    Type: Application
    Filed: January 8, 2015
    Publication date: November 17, 2016
    Inventors: Adrian U. Wiestner, Martin W. Skarzynski, Margaret A. Lindorfer, Ronald P. Taylor, Christoph Rader, Berengere Vire
  • Enhancing the efficacy of immunotherapies by supplementing with complement
    Patent number: 7858087
    Abstract: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope). More particularly the present invention enhances the efficacy of such therapies by providing a supplemental source of complement.
    Type: Grant
    Filed: July 25, 2007
    Date of Patent: December 28, 2010
    Assignee: University of Virginia Patent Foundation
    Inventors: Ronald P. Taylor, Margaret A. Lindorfer, Michael D. Solga, Adam Kennedy
  • Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
    Patent number: 7837997
    Abstract: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
    Type: Grant
    Filed: December 18, 2006
    Date of Patent: November 23, 2010
    Assignees: Trustees of the University of Pennsylvania, University of Virginia Patent Foundation
    Inventors: Vladimir R. Muzykantov, Abd Al-Roof Higazi, Juan Carlos Murciano, Douglas Cines, Ronald P. Taylor
  • Compositions and Methods for Regulating the Alternative Pathway of Complement
    Publication number: 20090004183
    Abstract: The present invention provides compositions and methods for regulating the alternative complement pathway.
    Type: Application
    Filed: July 25, 2005
    Publication date: January 1, 2009
    Inventors: Ronald P. Taylor, David John Dilillo, Margaret A. Lindorfer, Andrew W. Pawluczkowycz
  • Therapeutic uses of complement receptor 2
    Patent number: 7378094
    Abstract: The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % A1488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.
    Type: Grant
    Filed: August 28, 2002
    Date of Patent: May 27, 2008
    Assignee: University of Virginia Patent Foundation
    Inventors: Ronald P. Taylor, Margaret A. Lindorfer, William M. Sutherland
  • Enhancing the efficacy of immunotherapies by supplementing with complement
    Patent number: 7255858
    Abstract: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope). More particularly the present invention enhances the efficacy of such therapies by providing a supplemental source of complement.
    Type: Grant
    Filed: August 9, 2002
    Date of Patent: August 14, 2007
    Assignee: University of Virginia Patent Foundation
    Inventors: Ronald P. Taylor, Margaret A. Lindorfer, Michael D. Solga, Adam Kennedy
  • Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
    Patent number: 7172760
    Abstract: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
    Type: Grant
    Filed: September 23, 2002
    Date of Patent: February 6, 2007
    Assignees: Trustees of the University of Pennsylvania, University of Virginia Patent Foundation
    Inventors: Vladimir R. Muzykantov, Abd Al-Roof Higazi, Juan Carlos Murciano, Douglas Cines, Ronald P. Taylor
  • Therapeutic uses of complement receptor 2
    Publication number: 20040191252
    Abstract: The present invention is directed to an immune complex composition, and a method of using that complex to enhance an in viva immune response against a preselected target antigen. The immune complexes of the present invention comprise a monoclonal antibody specific for binding to complement receptor (CR2) site on B lymphocytes linked to a target antigen. As shown in FIG. SA-SD immune complexes bound to monkey B cells are removed in concert with loss of CR2. FIGS. SA and SB demonstrate the % AI488 HB135 and % APhCy CD21 positive cells, out of the doubly positive FE CD20/PerCF CD45 population over time, after injection of A1488 labeled HB135 (an anti-CR2 antibody, administration indicated by first arrow) followed by injection of rabbit anti-mouse IgG (administration indicated by the second arrow). FIGS. SC and SD are plots of the molecules of equivalent soluble fluorochome (MESF) values for these populations.
    Type: Application
    Filed: February 27, 2004
    Publication date: September 30, 2004
    Inventors: Ronald P. Taylor, Margaret A. Lindorfer, William M. Sutherland
  • Enhancing the efficacy of immunotherapies by supplementing with complement
    Publication number: 20040170633
    Abstract: The present invention is directed to a composition and method for enhancing the complement-mediated cytotoxicity of therapeutic antibodies for their target cells (i.e. those cells displaying the target epitope).
    Type: Application
    Filed: February 9, 2004
    Publication date: September 2, 2004
    Inventors: Ronald P Taylor, Margaret A. Lindorfer, Michael D. Solga, Adam A. Kennedy
  • Hydrophobic light stable polyurethane elastomer with improved mechanical properties
    Patent number: 6780957
    Abstract: A hydrophobic polyurethane elastomer is disclosed comprising an isocyanate terminated prepolymer having an isocyanate content ranging from 4 to 12 wt. % NCO comprising the reaction product of: i) an OH terminated homopolymer of butadiene having molecular weight ranging from 1000 to 4000 and an OH functionality of from 1.9 to 2.1; ii) an aliphatic or cycloaliphatic diisocyanate; and a diol chain extender having a molecular weight ranging from 62 to 400.
    Type: Grant
    Filed: December 29, 1999
    Date of Patent: August 24, 2004
    Assignee: Bayer Polymers LLC
    Inventors: Karl W. Haider, Jack C. Chan, E. Haakan Jonsson, Uli W. Franz, Ronald P. Taylor
  • Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots
    Publication number: 20030152563
    Abstract: Compositions and methods for prevention and treatment of uncontrolled formation of intravascular fibrin clots are provided wherein fibrinolytic or anticoagulant drugs are biocompatibly coupled to red blood cell carriers.
    Type: Application
    Filed: September 23, 2002
    Publication date: August 14, 2003
    Inventors: Vladimir R. Muzykantov, Abd Al-Roof Higazi, Juan Carlos Murciano, Douglas Cines, Ronald P. Taylor
  • Antigen-based heteropolymers and method for treating autoimmune diseases using the same
    Publication number: 20020103343
    Abstract: Constructs consisting of antigen-based heteropolymers (AHP's) are provided. The antigen-based heteropolymers comprise at least one monoclonal antibody specific for binding to complement receptor (CR1) site on a human or non-human primate erythrocyte, and the anti-CR1 monoclonal antibody is crosslinked to an antigen specific for a target pathogenic autoantibody. Further provided is a method for treating autoimmune diseases in human or non-human primates using the AHP.
    Type: Application
    Filed: October 26, 2001
    Publication date: August 1, 2002
    Applicant: University of Virginia Alumni Patents Foundation
    Inventors: Ronald P. Taylor, Polly J. Ferguson, Edward N. Martin, William S. Sutherland, Craig J. Reist, Kirsten Greene, Cyd Johnson
  • Plasticizers for bowling ball coverstocks
    Patent number: 6407201
    Abstract: The present invention provides a plasticizer compound having the general formula: in which n=1 to 3, R represents a C2-C8 straight or branched aliphatic hydrocarbon chain or C6-C10 aromatic or cycloaliphatic group, and R′ and R″ are each independently a branched oxyalkylene chain represented by the chemical formula C8H16O and by the chemical structures: The present invention is also directed to a coverstock formulation comprising the above-plasticizer compound.
    Type: Grant
    Filed: August 21, 2000
    Date of Patent: June 18, 2002
    Assignee: Bayer Corporation
    Inventors: Ronald P. Taylor, Jeffrey A. Dodge, Hartmut Nefzger
  • Composition and process for preparation of thermoplastic polyurethanes (TPU based on a polybutadiene soft segment)
    Patent number: 6166166
    Abstract: A process for making a thermoplastic polyurethane material comprising the steps of casting an NCO-terminated prepolymer with 1,4-butanediol to form a casting composition; extruding the casting composition to form at least one strand of a polyurethane elastomer; pelletizing the at least one strand of said polyurethane elastomer to form at least one pellet; and processing the at least one pellet to form a thermoplastic article.
    Type: Grant
    Filed: August 26, 1998
    Date of Patent: December 26, 2000
    Assignee: Bayer Corporation
    Inventors: Ronald P. Taylor, Jack C. Chan, Karl W. Haider, E. Haakan Jonsson, Uli W. Franz, Mark A. Peters
  • Polyurethane polyolefins and prepolymers based on hydroxy functional polybutadiene
    Patent number: 5990340
    Abstract: A di-hydroxy-functionalized linear non-crosslinked polyolefin is disclosed having no pendant chain-branched groups which is prepared by reacting 1,4-diacetoxy-2-butene with 1,5-cyclooctadiene in the presence of a catalyst comprising a ruthenium metal carbene complex, characterized in that the functionality number of said polyolefin as determined by NMR is 2.0 and the viscosity of said polyolefin ranges from about 800 to 16000 mPa.s @25.degree. C. at a number average molecular weight ranging from 2,600 to 6,500 g/mole. A prepolymer comprising the reaction of a polyisocyanate with the polyolefin is also disclosed.
    Type: Grant
    Filed: December 30, 1998
    Date of Patent: November 23, 1999
    Assignee: Bayer Corporation
    Inventors: Karl W. Haider, Jack C. Chan, E. Haakan Jonsson, Uli W. Franz, Mark A. Peters, Ronald P. Taylor
  • Antigen-based heteropolymers and method for treating autoimmune diseases using the same
    Patent number: 5879679
    Abstract: Constructs consisting of antigen-based heteropolymers (AHP's) are provided. The antigen-based heteropolymers comprise at least one monoclonal antibody specific for binding to complement receptor (CR1) site on a human or non-human primate erythrocyte, and the anti-CR1 monoclonal antibody is crosslinked to an antigen specific for a target pathogenic autoantibody. Further provided is a method for treating autoimmune diseases in human or non-human primates using the AHP.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: March 9, 1999
    Assignee: University of Virginia Alumni Patents Foundation
    Inventors: Ronald P. Taylor, Polly J. Ferguson, Edward N. Martin, Jr., William M. Sutherland, Craig J. Reist, Kirsten Greene, Cyd Johnson
  • Mammalian primate erythrocyte bound heteropolymerized monoclonal antibodies and methods of use thereof
    Patent number: 5487890
    Abstract: Mammalian red blood cells are used to safely and rapidly neutralize and/or clear antigens or immunogens from the circulatory system by binding to the RBC a monoclonal antibody specific for a receptor (CR1) on the RBC, which monoclonal antibody is chemically bound to a second Mab specific for the antigen to be cleared from the circulatory system. These chemically cross-linked monoclonal antibody heteropolymers may be injected directly into the patient's circulatory system. Alternatively, red blood cells, extracted from the patient or provided by a suitable donor, are bound to the Mab complex and returned to the system.
    Type: Grant
    Filed: January 24, 1994
    Date of Patent: January 30, 1996
    Assignee: University of Virginia Patent Foundation
    Inventors: Ronald P. Taylor, William M. Sutherland, Craig Reist, Eleanor L. Wright, Donna Webb, Ronald Labuguen